Abstract

Objective To investigate the role of Sestrin2 in the regulation of miR-19-induced epithelial-mesenchymal transition (EMT) in non-small cell lung cancer cells. Methods The experiment had a control group, an miR-19 overexpression group, and a Liushen pills group. The control group was normal serum-cultured A549 cells, the miR-19 overexpression group was normal serum-cultured miR-19 overexpressing A549 cells, and the Liushen pill group was Liushen pills-containing serum-cultured the miR-19 overexpression of A549 cells. CCK-8 was used to detect A549 cell proliferation, Transwell chamber was used to detect A549 cell migration capability, real-time quantitative PCR (RT-PCR) was used to detect the miR-19 expression, and western blot was used to detect the protein levels of Sestrin2, PTEN, and EMT markers including E-cadherin and Vimentin in 48 hours later. Results The cell counting kit-8 (CCK-8) showed that the proliferation rate of A549 cells was significantly slower in the Liushen pill group than in the control group and the miR-19 overexpression group. Transwell chamber test showed that the number of A549 cell migration was significantly lower in the Liushen pill group than in the miR-19 overexpression group and the control group. qRT-PCR showed that the miR-19 expression of A549 cells was significantly lower in the Liushen pill group than in the miR-19 overexpression group and the control group. Western blot showed that the expressions of Sestrin2, E-cadherin, and PTEN was significantly more up-regulated and that of Vimentin was more down-regulated in A549 cells in the Liushen pill group than in the control group and the miR-19 overexpression group. Conclusion Liushen pills can inhibit EMT in human lung adenocarcinoma cell line A549 induced by miR-19, which is related to the activation of Sestrin2 signaling pathway. Key words: Liushen pills; Epithelial-mesenchymal transformation; Sestrin2; miR-19

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.